Eli Lilly’s heart drug underwhelms with REWIND trial
pharmafile | June 11, 2019 | News story | Manufacturing and Production | Eli Lilly, Trulicity, pharma
Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according to the results of the REWIND trial.
The study of 9901 adults with type 2 diabetes looked at the glucagon-like peptide 1 receptor agonist Trulicity in combination with standard of care treatment in comparison to standard of care treatment combined with placebo.
While Lilly’s drug was effective in reducing major cardiovascular events the drug failed to meet the expectations of investors. According to MarketWatch Cowen analysts said investors had expected at least 20% risk reduction.
Shares in the Indianapolis-based firm fell by 2.4% in premarket trading.
Louis Goss
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets
Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) …
Isomorphic Labs to collaborate with Eli Lilly
Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli …